

# Stanford

---



## Won suk Jahng

Instructor, Cardiovascular Institute

### Bio

---

#### ACADEMIC APPOINTMENTS

- Instructor, Cardiovascular Institute

#### HONORS AND AWARDS

- TRISH Postdoctoral Fellowship, TRISH/NASA (2021-2023)
- TRAM pilot grant, Stanford University (2021-2022)

### Publications

---

#### PUBLICATIONS

- **Generation of induced pluripotent stem cell lines from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene.** *Stem cell research*  
Ren, L., Jahng, J. W., Belbachir, N., Cook, Z., Rivero, G. C., Perez, M. V., Wu, J. C.  
2024; 78: 103443
- **Incomplete-penetrant hypertrophic cardiomyopathy MYH7 G256E mutation causes hypercontractility and elevated mitochondrial respiration.** *Proceedings of the National Academy of Sciences of the United States of America*  
Lee, S., Vander Roest, A. S., Blair, C. A., Kao, K., Bremner, S. B., Childers, M. C., Pathak, D., Heinrich, P., Lee, D., Chirikian, O., Mohran, S. E., Roberts, B., Smith, et al  
2024; 121 (19): e2318413121
- **Elucidating effects of the environmental pollutant benzo[a]pyrene [BaP] on cardiac arrhythmogenicity.** *Journal of molecular and cellular cardiology*  
Yang, J. Y., Mondéjar-Parreño, G., Jahng, J. W., Lu, Y., Hamburg, N., Nadeau, K. C., Conklin, D. J., Liao, R., Chandy, M., Wu, J. C.  
2024; 191: 23-26
- **Generation of two induced pluripotent stem cell lines from patients suffering from pulmonary hypertension.** *Stem cell research*  
Chen, G., Orozco, L., Parmisano, S., Jahng, J. W., Vera, C. D., Zhuge, Y., Wu, J. C., Obal, D.  
2023; 72: 103218
- **SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant.** *Science translational medicine*  
Guo, H., Yu, X., Liu, Y., Paik, D. T., Justesen, J. M., Chandy, M., Jahng, J. W., Zhang, T., Wu, W., Rwere, F., Zhao, S. R., Pokhrel, S., Shivnaraine, et al  
2023; 15 (680): eabp9952
- **Ferroptosis of Pacemaker Cells in COVID-19.** *Circulation research*  
Nishiga, M., Jahng, J. W., Wu, J. C.  
2022; 130 (7): 978-980
- **Generation of two iPSC lines from hypertrophic cardiomyopathy patients carrying MYBPC3 and PRKAG2 variants.** *Stem cell research*  
Manhas, A., Jahng, J. W., Vera, C. D., Shenoy, S. P., Knowles, J. W., Wu, J. C.  
2022; 61: 102774

- **Cardiac reprogramming via chromatin remodeling by CRISPR activation.** *Molecular therapy : the journal of the American Society of Gene Therapy*  
Jahng, J. W., Wu, J. C.  
1800
- **Generation of three induced pluripotent stem cell lines (SCVi014-A, SCVi015-A, and SCVi016-A) from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene.** *Stem cell research*  
Zhang, H., Jahng, J. W., Liu, Y., Chase, A. J., Perez, M. V., Wu, J. C.  
2021; 55: 102492
- **Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations.** *Stem cell research*  
Cao, X., Jahng, J. W., Lee, C., Zha, Y., Wheeler, M. T., Sallam, K., Wu, J. C.  
2021; 55: 102455
- **The role of metabolism in directed differentiation versus trans-differentiation of cardiomyocytes.** *Seminars in cell & developmental biology*  
Jahng, J. W., Zhang, M., Wu, J. C.  
2021
- **Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome.** *Stem cell research*  
Mondejar-Parreno, G., Jahng, J. W., Belbachir, N., Wu, B. C., Zhang, X., Perez, M. V., Badhwar, N., Wu, J. C.  
2021; 54: 102402
- **Generation of three induced pluripotent stem cell lines, SCVi003-A, SCVi004-A, SCVi005-A, from patients with ARVD/C caused by heterozygous mutations in the PKP2 gene.** *Stem cell research*  
Jahng, J. W., Black, K. E., Liu, L., Bae, H. R., Perez, M., Ashley, E. A., Sallam, K., Wu, J. C.  
2021; 53: 102284
- **Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVi001-A and SCVi002-A, for modeling hypertrophic cardiomyopathy.** *Stem cell research*  
Liu, L., Shenoy, S. P., Jahng, J. W., Liu, Y., Knowles, J. W., Zhuge, Y., Wu, J. C.  
2021; 53: 102279
- **Tumor Repressor Circular RNA as a New Target for Preventative Gene Therapy Against Doxorubicin-Induced Cardiotoxicity.** *Circulation research*  
Jahng, J. W., Liu, L. n., Wu, J. C.  
2020; 127 (4): 483–85